Merkel Cell Carcinoma - Pipeline Review, 2019
Firstview Insight's Keratoconjunctivitis sicca (Dry Eye) - Pricing and Market Access provides country specific insights in order to estimate market potential for Keratoconjunctivitis sicca (Dry Eye) based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing & Market Access landscape.
Dry eyes or dry eye syndrome is a condition in which the eyes do not produce enough tears. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye.The multi-screen modern lifestyle which includes eye strain due to more usage of the tablet, mobile, and computer screens are responsible for triggering the eye related problems. Products are categorized in the report by Liquid Drops, Gel, Liquid Wipes, Eye Ointment etc.
LIST OF PRODUCTS
Market Access strategy for different payer archetypes
Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. cost-effectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.
Payer Policy changes and implications
Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.
Innovative pricing and funding mechanisms
With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.
Disease Overview
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines
Epidemiology
This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan.
Existing and upcoming treatment landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.
Market Trends & Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Major highlights of the report
Detailed analysis of existing and upcoming competitive landscape
HTA decisions and benefit ratings for :
NICE (UK)
GBA (Germany)
HAS(ASMR and SMR)(France)
AIFA (Italy)
AEMPS (Spain)
SMC (Scotland)
ICER (US)
Chuikyo (Japan)
Market archetyping and product positioning
Case studies on innovative funding models
Unmet need, major barriers and drivers across the industry:
Value story for achieving reimbursement and premium pricing in different markets
Dry eyes or dry eye syndrome is a condition in which the eyes do not produce enough tears. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye.The multi-screen modern lifestyle which includes eye strain due to more usage of the tablet, mobile, and computer screens are responsible for triggering the eye related problems. Products are categorized in the report by Liquid Drops, Gel, Liquid Wipes, Eye Ointment etc.
LIST OF PRODUCTS
- Synthetic lacritin - TearSolutions
- RX 10045
- Ciclosporine/trehalose
- Estradiol 3-phosphate controlled-release
- OC-02
- recombinant human lacritin
- Ciclosporin (CEQUA)
- Ciclosporin (RESTASIS)
- Rebamipide (Mucosta)
- Tavilermide
- Timbetasin
- Tivanisiran
- TOP 1630
- Zucapsaicin
- Cinhyaluronate sodium
- P-321
- SA-001
Market Access strategy for different payer archetypes
Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. cost-effectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.
Payer Policy changes and implications
Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.
Innovative pricing and funding mechanisms
With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.
Disease Overview
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines
Epidemiology
This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan.
Existing and upcoming treatment landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.
Market Trends & Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Major highlights of the report
Detailed analysis of existing and upcoming competitive landscape
HTA decisions and benefit ratings for :
NICE (UK)
GBA (Germany)
HAS(ASMR and SMR)(France)
AIFA (Italy)
AEMPS (Spain)
SMC (Scotland)
ICER (US)
Chuikyo (Japan)
Market archetyping and product positioning
Case studies on innovative funding models
Unmet need, major barriers and drivers across the industry:
Value story for achieving reimbursement and premium pricing in different markets
1. DISEASE OVERVIEW
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING MERKEL CELL CARCINOMA
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES9. LATE STAGE PRODUCTS (PHASE III)
9.1 XXX
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. XXX
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities10. Mid Stage Products (Phase II)
10.1 Cabozantinib
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Tavokinogene telseplasmid
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Domatinostat
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Merkel cell carcinoma therapies - Vironika
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF MERKEL CELL CARCINOMA
13. CONSTRAINTS OF MERKEL CELL CARCINOMA
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING MERKEL CELL CARCINOMA
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES9. LATE STAGE PRODUCTS (PHASE III)
9.1 XXX
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. XXX
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities10. Mid Stage Products (Phase II)
10.1 Cabozantinib
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Tavokinogene telseplasmid
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Domatinostat
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Merkel cell carcinoma therapies - Vironika
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF MERKEL CELL CARCINOMA
13. CONSTRAINTS OF MERKEL CELL CARCINOMA
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
LIST OF TABLES
Table 1: Marketed Merkel Cell Carcinomadrugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for Merkel Cell Carcinoma
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
Table 1: Marketed Merkel Cell Carcinomadrugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for Merkel Cell Carcinoma
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
LIST OF FIGURES
Figure 1: Marketed and PipelineMerkel Cell Carcinoma - Pipeline Review, 2019drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for Merkel Cell Carcinoma - Pipeline Review, 2019
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
Figure 1: Marketed and PipelineMerkel Cell Carcinoma - Pipeline Review, 2019drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for Merkel Cell Carcinoma - Pipeline Review, 2019
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
